Nifedipine

Generic Name: Nifedipine

Brand Names: Adalat, Afeditab CR, Nifediac, Nifedical, Procardia

Drug Type: Small Molecule

Chemical Formula: C_₁₇H_₁₈N_₂O_₆

CAS Number: 21829-25-4

Unique Ingredient Identifier: I9ZF7L6G2L

Background: Nifedipine, or BAY a 1040, is a first generation dihydropyridine L-type calcium channel blocker, similar to nicardipine. Nifedipine was developed by Bayer and first described in the literature, along with other dihydropyridines, in 1972. Since nifedipine's development, second and third generation dihydropyridines have been developed with slower onsets and longer durations of action. The most popular of the third generation dihydropyridines is amlodipine.

Nifedipine was granted FDA approval on 31 December 1981.

Indication: Nifedipine capsules are indicated to treat vasospastic angina and chronic stable angina. Extended release tablets are indicated to treat vasospastic angina, chronic stable angina, and hypertension.

Associated Conditions: Achalasia, Chronic Stable Angina Pectoris, Fissure;Anal, Hypertension, Hypertensive Emergency, Premature Labour, Proctalgia, Pulmonary Edemas, Pulmonary Hypertension (PH), Raynaud's Phenomenon, Ureteral Calculus, Vasospastic Angina

Clinical Trials

Tocolytic Therapy in Conservative Management of Symptomatic Placenta Previa

Phase 2

Completed

Conditions: Placenta Previa

Interventions: Drug: Nifedipine
Drug: Placebo

First Posted Date: 2008-02-21

Last Posted Date: 2014-07-10

Lead Sponsor: University Hospital, Rouen

Target Recruit Count: 109

Registration Number: NCT00620724

Locations: 🇫🇷
University Hospital Rouen, Rouen, France

Nifedipine Compared to Atosiban for Treating Preterm Labor

Phase 4

Completed

Conditions: Labor, Premature

Interventions: Drug: Atosiban
Drug: Nifedipine

First Posted Date: 2008-01-24

Last Posted Date: 2012-03-13

Lead Sponsor: Raed Salim

Target Recruit Count: 145

Registration Number: NCT00599898

Locations: 🇮🇱
HaEmek Medical Center, Afula, Israel

Drug Discrimination in Methadone-Maintained Humans Study 1

Phase 1

Completed

Conditions: Drug Dependence

Interventions: Drug: Cycloserine
Drug: Diltiazem
Drug: Gabapentin
Drug: Isradipine
Drug: Naloxone
Drug: Nifedipine
Drug: Placebo
Device: Saline
Drug: Verapamil

First Posted Date: 2008-01-15

Last Posted Date: 2011-03-11

Lead Sponsor: University of Arkansas

Target Recruit Count: 40

Registration Number: NCT00593463

Locations: 🇺🇸
University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States

Extended Release Nifedipine Treatment as Maintenance Tocolysis to Prevent Preterm Delivery

Not Applicable

Terminated

Conditions: Preterm Labor

Interventions: Drug: Nifedipine extended release

First Posted Date: 2007-09-05

Last Posted Date: 2010-12-23

Lead Sponsor: The Baruch Padeh Medical Center, Poriya

Registration Number: NCT00525486

Efficacy Study of Topical Application of Nifedipine Cream to Treat Vulvar Vestibulitis

Phase 3

Completed

Conditions: Vulvar Diseases
Vulvar Pain
Vestibulitis
Vestibulodynia
Vulvodynia

First Posted Date: 2007-07-04

Last Posted Date: 2008-05-08

Lead Sponsor: Western Galilee Hospital-Nahariya

Target Recruit Count: 30

Registration Number: NCT00496184

Locations: 🇮🇱
Colposcopy Clinic, Obstetrics and Gynecology Department, Western galilee Hospital, Nahariya, Israel
🇮🇱
Department of Obstetrics and Gynecology, Nahariya, Israel